For the quarter ending 2026-03-31, VANI had $3,517K increase in cash & cash equivalents over the period. -$6,199K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Personnel and related expenses | - | 11,414 | - | - |
| Office space rental related expenses | - | 4,532 | - | - |
| Biopharm Division | - | 4,329 | - | - |
| Neurostimulation Division | - | 0 | - | - |
| Development expenses | - | 4,329 | - | - |
| Professional services and insurance | - | 5,747 | - | - |
| Depreciation | - | 424 | - | - |
| Other general and administrative expenses | - | 1,110 | - | - |
| Biopharm Division | - | 821 | - | - |
| Neurostimulation Division | - | 126 | - | - |
| Other income (expense), net | - | 947 | - | - |
| Net loss | -6,780 | -6,633 | -6,530 | -13,446 |
| Depreciation and amortization | 130 | 115 | 105 | 204 |
| Stock-based compensation | 312 | 467 | 276 | 741 |
| Reclassification of foreign currency translation adjustments | - | 117 | - | - |
| Equipment write-off and loss on equipment disposal | - | 0 | - | - |
| Non-cash lease expense | 34 | 116 | 39 | 114 |
| Fixed assets write-off | - | - | 0 | 0 |
| R&d tax credit incentive receivable | 43 | -10 | 170 | 241 |
| Prepaid expenses and other assets | 141 | 154 | -650 | -412 |
| Accounts payable | 433 | -396 | -759 | 933 |
| Accrued compensation expenses | -16 | 8 | 1 | 13 |
| Accrued expenses | -125 | -135 | 37 | 20 |
| Net cash used in operating activities | -6,196 | -6,719 | -6,351 | -11,250 |
| Purchases of property and equipment | 3 | 274 | 823 | 76 |
| Net cash used in investing activities | -3 | -274 | -823 | -76 |
| Proceeds from issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs | - | 0 | 0 | 0 |
| Proceeds from issuance of common stock in connection with the sales agreement, net of issuance costs | - | -28 | - | 0 |
| Proceeds from issuance of common stock in connection with director private securities purchase agreement, net of issuance costs | - | 0 | - | - |
| Proceeds from issuance of common stock in connection with 2025 private sales transaction, net of issuance costs | - | 8,543 | - | - |
| Issuance of common stock in connection with 2025 private sales transactions | 5,650 | - | - | - |
| Issuance of common stock in connection with 2026 registered direct offering, net of issuance costs | 2,174 | 8,748 | - | - |
| Issuance of common stock in connection with the 2025 private sales transaction, net of issuance costs | - | - | 2,593 | - |
| Issuance of common stock in connection with 2026 private placement, net of issuance costs | 1,997 | 6,000 | - | - |
| Gross proceeds from insurance premium loan | - | 0 | 355 | - |
| Payments on insurancepremiumloan | -107 | -107 | 0 | -237 |
| Net issuance costs in connection with the sales agreement | - | - | - | 28 |
| Net proceeds from issuance of common stock in connection with the sales agreement, net of issuance costs | - | - | -28 | - |
| Net issuance costs in connection with the sales agreement | 0 | - | - | - |
| Net cash provided by (used in) financing activities | 9,714 | 20,591 | 2,948 | -265 |
| Effect of exchange rate changes on cash and cash equivalents | 2 | 6 | 60 | 33 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 3,517 | 13,604 | -4,166 | -11,558 |
| Cash, cash equivalents and restricted cash balance at beginning of period | 17,570 | 3,966 | 19,690 | - |
| Cash, cash equivalents and restricted cash balance at end of period | 21,087 | 17,570 | 3,966 | - |
Vivani Medical, Inc. (VANI)
Vivani Medical, Inc. (VANI)